Woodcock Taps Temple To Tackle Controversial Issues; Stein Heads OND

December 07, 2018
FDA’s Bob Temple, a drug center veteran of 46 years, will soon become senior advisor for the Office of New Drugs’ Immediate Office -- becoming the center’s point person on medical decisions that are controversial, complex or critical, center director Janet Woodcock said in an internal email on Friday (Dec. 7). Temple will advise Peter Stein, currently deputy director of the drug center, who has been tapped permanent director of the Office of New Drugs, Woodcock announced in a separate...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.